UroGen Pharma (NASDAQ:URGN) Earns Buy Rating from HC Wainwright
UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $55.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 457.24% from the company’s previous close. URGN has been […]
UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $55.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 457.24% from the company’s previous close. URGN has been […]
